Sustainable Insight Capital Management LLC Acquires 900 Shares of Eli Lilly and Company (NYSE:LLY)

Key Points

• Sustainable Insight Capital Management LLC increased its stake in Eli Lilly and Company by 10.6% during the first quarter, now holding shares worth approximately $7.74 million.
• Insider activity includes Director Jamere Jackson purchasing 200 shares at around $639.56 per share, increasing his total holdings to 9,402 shares.
• Research analysts have issued several downgrades and adjusted price targets for Eli Lilly, with the consensus rating classified as a "Moderate Buy" and an average price target of $977.65.

Sustainable Insight Capital Management LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 10.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,367 shares of the company's stock after purchasing an additional 900 shares during the period. Eli Lilly and Company accounts for 3.9% of Sustainable Insight Capital Management LLC's holdings, making the stock its 9th biggest position. Sustainable Insight Capital Management LLC's holdings in Eli Lilly and Company were worth $7,736,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of LLY. WestEnd Advisors LLC boosted its position in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after acquiring an additional 21 shares during the last quarter. Citizens National Bank Trust Department lifted its stake in Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after purchasing an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. acquired a new position in shares of Eli Lilly and Company during the 1st quarter worth approximately $40,000. Mascagni Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $43,000. Finally, O Brien Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after purchasing an additional 12 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, Director J Erik Fyrwald bought 1,565 shares of the business's stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Daniel Skovronsky purchased 1,000 shares of the stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the transaction, the executive vice president directly owned 137,660 shares of the company's stock, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 4,514 shares of company stock worth $2,894,841 in the last 90 days. Insiders own 0.13% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Cantor Fitzgerald set a $825.00 target price on Eli Lilly and Company and gave the company an "overweight" rating in a report on Wednesday. Morgan Stanley restated an "overweight" rating and set a $1,135.00 price objective (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Wall Street Zen upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. UBS Group reduced their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Finally, Leerink Partnrs lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus price target of $964.88.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock traded up $24.78 during mid-day trading on Thursday, reaching $685.27. The company had a trading volume of 8,317,123 shares, compared to its average volume of 4,136,195. The stock's 50-day simple moving average is $767.52 and its 200-day simple moving average is $796.25. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $972.53. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company has a market capitalization of $648.58 billion, a P/E ratio of 44.79, a P/E/G ratio of 0.90 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%. Eli Lilly and Company's quarterly revenue was up 37.6% on a year-over-year basis. During the same period last year, the business posted $3.92 EPS. On average, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is presently 39.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.